Protalix BioTherapeutics, Inc. has completed a private stock placement
Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.
Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.


Talk to the deal team



Related deals
Kardan Real Estate has issued bonds
Kardan Real Estate Ltd. has completed a fundraising to develop the business.
Learn moreAce Pharmaceuticals has been acquired by Gilde Buy Out Partners, Gilde Healthcare and Quadrum Capital
Ace Pharmaceuticals BV has been acquired by Gilde Buy Out Partners, Gilde Healthcare, Quadrum Capital and the management team.
Learn moreUniversal Motors Israel has issued bonds
Universal Motors Israel Ltd. (UMI) has completed a fundraising to develop the business.
Learn more